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Abstract
Due to brain plasticity, the nervous system is capable of manifesting behavioral
variations, adapted to the influences from both external and internal environment.
Multiple neurotransmitters are involved in the mediation of pathological processes
at the molecular, cellular, regional, and interregional levels participating in cerebral
plasticity, their intervention being responsible for various structural, functional,
and behavioral disturbances. The current therapeutic strategies in neuroprotection
aim at blocking on different levels, the molecular cascades of the pathophysiological
mechanisms responsible for neuronal dysfunctions and ultimately for neuronal
death. Different agents influencing these neurotransmitters have demonstrated
beneficial effects in neurogenesis and neuroprotection, proved in experimental
animal models of focal and global ischemic injuries. Serotonin, dopamine, gluta-
mate, N-methyl-D-aspartate, and nitric oxide have been shown to play a significant
role in modulating nervous system injuries. The imidazoline system is one of the
important systems involved in human brain functioning. Experimental investiga-
tions have revealed the cytoprotective effects of imidazoline I2 receptor ligands
against neuronal injury induced by hypoxia in experimental animals. The
neuroprotective effects were also highlighted for kappa and delta receptors, whose
agonists demonstrated the ability to reduce architectural lesions and to recover
neuronal functions of animals with experimentally induced brain ischemia.
Keywords: neuroprotection, neurodegenerative diseases, ischemic stroke,
imidazoline, opioids, nitric oxide
1. Introduction
Increase in life expectancy has led to aging of the population and consequently
to an expansion of the prevalence of neurodegenerative diseases (NDDs) [1].
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Neurodegeneration represents a loss of neurons and their structural components
(dendrites, axons, and synapses) with a corresponding gradual atrophy in neuronal
function [2].
Clinical type Disease/disorder
Signs of progressive dementia
with no other neurological signs
(absent/inconspicuous)
• Alzheimer’s disease
• Frontotemporal dementias
• Some cases of Lewy-body disease
• Posterior cortical atrophy (visuospatial dementia)
Signs of progressive dementia
accompanied by other
neurological abnormalities
• Huntington’s disease (chorea)
• Lewy-body disease (Parkinsonian features)
• Some cases of Parkinson’s disease
• Corticobasal ganglionic degeneration
• Cortical-striatal-spinal degeneration (Jakob’s disease)
• Dementia-Parkinson-amyotrophic lateral sclerosis complex
• Cerebrocerebellar degeneration
• Familial dementia with spastic paraparesis, amyotrophy, or
myoclonus
• Polyglucosan body disease
• Frontotemporal dementia with parkinsonism or ALS
Signs of movement disorders or
other posture abnormalities • Parkinson’s disease
• Multiple system atrophy
• Essential tremor
• Progressive supranuclear palsy
• Dystonia musculorum deformans
• Huntington’s disease (chorea)
• Acanthocytosis with chorea
• Corticobasal ganglionic degeneration
• Lewy-body disease
• Restricted dystonia
Signs of progressive ataxia
• Spinocerebellar ataxias
• Cerebellar cortical ataxias
• Complicated hereditary and sporadic cerebellar ataxias
Signs of slowly developing
muscular weakness and atrophy • Motor disorders with amyotrophy
• Spastic paraplegia without amyotrophy
Sensory and sensorimotor
disorders • Hereditary sensorimotor neuropathies
• Pure or predominantly sensory or motor neuropathic
• Riley-Day autonomic degeneration
Signs of progressive blindness
with or without other
neurological disorders
• Pigmentary degeneration of retina
• Stargardt’s disease
• Age-related macular degeneration
Signs characterized by
degenerative neurosensory
deafness
• Pure neurosensory deafness
• Hereditary hearing loss with retinal diseases
• Hereditary hearing loss with system atrophies of the nervous
system
*Adapted from Ropper A, Samuels M, Klein J. Adams and Victor’s Principles of Neurology. 10th ed. McGraw-Hill
Education; 2014.
Table 1.
Neurodegenerative diseases: main clinical types.
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NDDs (e.g., Alzheimer’s disease, Parkinson’s disease, Huntington’s disease,
dementia with Lewy bodies) determine cognitive and memory deterioration or
alteration of the ability to move, speak, and breathe. These chronic and progressive
disorders are an important cause of reduced quality of life, morbidity, caregiver
burden and also, of the increase in total healthcare expenditure [3–5]. Table 1 lists
the main clinical types of NDDs [6].
Neuroprotection can be defined as a “relative preservation of neuronal structure
and/or function” or as an action that aims “to prevent neuronal damage over time
(either acute or chronic)” [7]. Neuroprotective action is primary if it is exerted
directly on the neuron, or secondary if it appears from an activity on an intermedi-
ary that endangers neuronal function [8].
The mechanisms by which most agents with efficiency in NDDs act are not fully
elucidated, requiring multiple and in-depth experimental and clinical studies.
Several experimental investigations highlight the multiple and various inter-
relations between adrenergic, serotoninergic, dopaminergic, glutamatergic, opi-
oid, imidazoline systems, and the nitric oxide pathways, which may elucidate
the effects of different compounds involved in the mediation of pathogenic
mechanisms responsible for numerous structural, functional, and behavioral
disturbances.
This chapter presents a brief overview of the most studied mechanisms related
to neuroprotection and details the possibilities to pharmacologically influence
through the main known neurotransmitters the pathophysiological mechanisms
linked to various NDDs.
2. The imidazoline system
Imidazoline receptors are located not only in the mammalian central nervous
system (CNS) cells but also in the peripheral nervous system [9], being involved in
the mediation of various physiological processes in the body. It is currently known
that there are four types of imidazoline receptors: I1, I2, I3, I4 (non I1-non I2), from
which the first three have been mostly studied [10].
It has been emphasized that these receptors play an essential role in cell prolif-
eration, regulation of adipose tissue formation, body temperature maintenance,
mediation of gastrointestinal motility, neuroprotection, inflammation, nociceptive
sensitivity, and some neurological or psychiatric disorders (such as depression)
[11]. Moreover, it is known that these imidazoline receptor subtypes exert control
over the activity of the hypothalamic-pituitary-adrenal and noradrenergic axis
[12, 13].
A number of different endogenous ligands have been characterized: agmatine,
the best known and largely studied, harmane and harmalane (derivatives of the
beta-carboline group), and the newly discovered ribotide (acetic acid imidazole).
Agmatine, the potent neurotransmitter of the imidazoline system, has an important
role in the mediation of body’s response to stress, analgesia, drug addiction, and
abstinence syndrome, in modulation of seizures development, and in
neuroprotection [14, 15].
Endogenous agmatine is produced in response to stress (in conditions of ische-
mia, prolonged exposure to cold) and/or to inflammation [16]. It is assumed that
agmatine is also an effective neurotransmitter, due to its concentration in the brain
similar to classical neurotransmitters [17, 18].
Literature data have revealed that agmatine stimulates the activity of endothelial
nitric oxide synthase [16], this effect being also proved by its level in the rat brain
after cerebral ischemia [19, 20].
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Along with evidence of its neuromodulatory and neuroprotective properties, there
are numerous preclinical studies demonstrating the beneficial effects of exogenous
administration of agmatine in depression, anxiety, hypoxic ischemia, pain, morphine
tolerance, memory impairment, Parkinson’s disease, Alzheimer’s disease, epilepsy,
and other related conditions with traumatic brain injuries (Figure 1) [21–23]. All
these are arguments in favor of the potential of agmatine as a new pharmacological
agent for the treatment of various neurological diseases and NDDs [24].
3. The involvement of the imidazoline system in the mediation of
cognitive functions
Electrophysiological studies involving various brain areas, performed on labora-
tory animals with experimentally induced cerebral alterations, have demonstrated
the neurotropic effects of agmatine [25].
In vitro experimental researches have shown that activation of I2 receptors via the
agmatine endogenous ligand exerts neuroprotective effects by increasing the
Figure 1.
Neuroprotective effects of agmatine and their first discovery.
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expression of glial fibrillary acidic protein in astrocyte cultures and by inhibiting
MAO activity [26, 27]. Moreover, the beneficial effects of agmatine have been
observed on ischemic-hypoxic lesions, on glutamate-induced neurotoxicity by acti-
vating the imidazoline receptors [28, 29]. It was also demonstrated that agmatine
administration improves learning activity andmemory of rats in experimental models
of Alzheimer’s disease and streptozotocin-induced type two diabetes mellitus [22, 30].
Other experimental investigations highlight the neuroprotective effect of intra-
nasal administration of agmatine in elderly female rats, with a significant improve-
ment of neurological status and increase of survival rate [28, 29].
The neuroprotective effects of agmatine on the morphological changes deter-
mined by repeated induced stress on medial prefrontal cortex and hippocampus of
the rat were also investigated [31]. It was emphasized that under constant stress
conditions, morphological alterations of the brain are associated with the reduction
of endogenous agmatine levels [measured by high-performance liquid chromatog-
raphy (HPLC)] and with an increase of arginine-decarboxylase level in the pre-
frontal cortex, hippocampus, striatum, and hypothalamus [32].
The exogenous administration of agmatine lowers brain morphological impair-
ment, suggesting thus its neuroprotective effects against structural changes in the
rat brain, under recurrent stress circumstances [32]. Moreover, elevated levels of
agmatine have been evidenced in the blood, cortex, hippocampus, and hypothala-
mus, immediately after brain hypoxic ischemia. Other studies emphasize the
neuroprotective influences of agmatine, highlighted by the increase of its brain
levels, in rats subjected to prolonged cold-exposure stress conditions [33].
The neuroprotective potential of agmatine was also highlighted in the experi-
mental model of 1-methyl-4-phenyltetrahydropyridine (MPTP)-induced
Parkinson’s disease in mice [29]. The use of agmatine attenuates the loss of cellular
dopamine from the black substance and repeated treatment improves short-term
memory impairment induced by MPTP in elderly mice. The behavioral benefits of
agmatine are associated with the decrease in MPTP-induced glutamate capture in
the hippocampal area, suggesting thus its involvement in modulation of glutamate
recapture, the possible mechanisms responsible for lowering glutamate extracellular
levels, thereby alleviating its neurotoxicity [29].
It is known that alteration of spatial memory in Parkinson’s disease and schizo-
phrenia is attributed to several factors, including hypofunction of glutamate and
reduction of hippocampal volume [34]. Literature data report that the administration
of the N-methyl-D-aspartate (NMDA) receptor antagonists (phencyclidine, also
coded MK801) frequently impairs the late alternation performance in a standardized
behavioral model of cognitive functions alteration similar to schizophrenia in labora-
tory animals [34]. The use of the glutamate/NMDA receptor antagonist phencyclidine
induces a spectrum of behavioral, neurochemical, and anatomical changes,
manifested by locomotor hyperactivity, motor-negative deficits, and cognition alter-
ations (with memory impairment and visual attention) in laboratory animals. This
substance was used to induce the experimental schizophrenia in laboratory animals
[35, 36]. Agmatine attenuates cognitive and behavioral deficiency in rats with exper-
imental phencyclidine-induced schizophrenic manifestations [37].
The effects of agmatine on memory alterations similar to those found in
Alzheimer’s disease have been evaluated in rats; in the pathogenesis of this degen-
erative disorder (which causes cognitive deficits in rodents), the fragment beta
amyloid Aβ2 25–35 plays an essential role. Studies have shown that agmatine signif-
icantly reduces the alterations in memory and spatial learning induced by the beta
amyloid Aβ2 25–35 fragment (the neurotoxic component of beta amyloid Aβ 1–42)
in various behavioral experimental models, such as: the swimming test, the radial
arm maze test, and the object recognition test [38].
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It has been revealed that agmatine diminishes the activation of hippocampal
caspase-3 (the early indicator of neuronal apoptosis) and prevents the alteration of
spatial memory induced by lipopolysaccharides, in the swimming test in rat [39],
suggesting its neuroprotective effects.
The neurotropic activity of agmatine has been also evidenced in the structural
and cognitive alterations after the administration of NMDA (N-methyl-D-
aspartate) in rats [40]. The use of high performance liquid chromatography
(HPLC) and electrochemical detection allowed highlighting that the treatment with
NMDA is associated with low concentrations of monoamines (epinephrine, norepi-
nephrine, dopamine, and serotonin) in rat PC12 cells [29, 40]. In this experimental
model (swimming test), agmatine protects against NMDA-induced PC12 cell
lesions, augmenting the levels of epinephrine, norepinephrine, and dopamine, but
not influencing serotonin values, together with lowering intracellular Ca2+ overload.
These results indicate that the neuroprotective action of agmatine may be related to
NMDA-receptor modulation and/or to controlling the decrease in monoamine con-
tent and NMDA-induced intracellular Ca2+ overload [40].
Immunohistochemical studies and electrophysiological investigations performed
on the brain have validated the neuroprotective actions of both imidazoline recep-
tor antagonists idazoxan and efaroxan in rats with cerebral damages caused by the
use of quinolinic acid [41], and also in mice with experimentally induced autoim-
mune encephalomyelitis, confirming the improvement of brain structural alter-
ations and blood brain barrier lesions curtail [42].
A new (+)2-(ethyl-2,3-dihydrobenzofuranyl)-2-imidazoline derivative—
dexefaroxan—the (+) enantiomer of efaroxan has been characterized. It has a
potent and selective α2 antagonist activity, with facultative effects on cognitive
functions in the passive avoidance test in rats with memory-deficiency induced by
scopolamine, diazepam, or by the 2-adrenergic agonist UK 14,304.
Dexefaroxan improves the cognitive performances in the passive avoidance test,
facilitates spatial memory in the Morris swimming test in rats, and increases the
object recognition ability in the specific behavioral test in mice [43, 44]. It has also
proved to ameliorate the animal’s memory deficits in these tests, particularly by
attenuation of spontaneous memory loss, and to improve their spatial recognition
ability, rather than through the acquisition skills or various other non-cognitive
effects.
After subcutaneous administration of dexefaroxan, its pharmacodynamic effects
persist for about 21–25 days, indicating that tolerance does not occur during
prolonged treatment. Moreover, it was emphasized that dexefaroxan exerts protec-
tive effects on the spatial memory deficit caused by cortical devascularization in the
Morris swimming test in rats [43].
Dexefaroxan has also been shown to exhibit neuroprotective effects on the de-
vascularization-induced neurodegeneration, to ameliorate the structural changes in
the hippocampus, and to remove the cognitive deficits induced by cerebral ischemia
in rats [45, 46]. Its neuroprotective effects were present also in the excitotoxic
lesions produced at the region of the basal magnocellular nucleus, increasing the
olfactory discriminative capacity of rats, suggesting thus the possibility of its use in
the treatment of memory disturbances in Alzheimer’s disease [43].
Studies performed on genetically modified animals revealed that dexefaroxan
improves cognitive performance in knockout mice with Alzheimer’s disease [47].
Literature data regarding the neuroprotective action of imidazoline agonist and
antagonist agents in human studies are only few, and the mechanisms involved in
these effects are not completely deciphered.
Some investigations suggested that agmatine manifests protective activity
against brain cell injury in different in vivo models of Parkinson’s disease, as well as
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in vitro studies, performed on human-derived dopaminergic neuroblastoma cell
lines. It was postulated that the neuromodulatory properties of agmatine are related
to the protective effects on the dopaminergic neurons, to NMDA receptor blocking,
and to the decrease in oxidative stress, due to the inhibition of nitric oxide synthase
(NOS) activity [48, 23].
Other clinical trials highlighted that the treatment with agmatine was associated
with cytoprotective actions, in patients with spinal cord injury, proved by lessening
the glial weal construction, decreasing the collagen scar zone, relieving the neuronal
alterations, and recovering remyelination [49]. Moreover, the beneficial effects of
agmatine have been demonstrated in various CNS lesions such as: cerebrovascular
accident, brain trauma, neuropathic pain, lumbar degenerative disc disease, and
different other types of neuropathy [50–52].
The administration of dexmedetomidine has also shown neuroprotective effects
in humans with acute cerebral lesions [53].
In patients with dementia due to brain frontal lesions, idazoxan alleviates atten-
tional and executive dysfunctions evoked by classical cognitive function tests [54].
4. The interrelation between the adrenergic and the imidazoline
systems in the mediation of cognitive functions
Clonidine, both a non-specific α2 adrenergic and imidazoline receptor agonist,
decreases the cognitive function alterations induced by phencyclidine and MK801,
facilitating spatial memory in the radial arm maze test in rats [35], but does not
influence the behavioral and cognitive deficits in the experimental NMDA-induced
excitotoxic dorsal hippocampal lesions [35]. Such findings indicate that clonidine
improves memory alterations caused by glutamate hypofunction, but not by hip-
pocampal injury, implying that multiple and distinct mechanisms are involved in
the development of memory disorders.
The administration of the α2 adrenergic receptor agonist clonidine or guanfacine
prevents some of the behavioral effects of NMDA antagonists, proving that the
monoaminergic system mediates a number of aspects of the cognitive deficit. Clo-
nidine and guanfacine improve the lack of visual attention and spatial memory
induced by phencyclidine in rats [34, 36]. It was demonstrated that low doses of
clonidine recover the animal’s ability to accurately choose the object and prevent the
performance deficit induced by phencyclidine. At high doses, clonidine decreases
the response time and induces a lack of the choice accuracy. These results indicate
that clonidine treatment can alleviate phencyclidine-induced deficit of attention
and of working memory, probably by preventing some of the neurochemical and
anatomical effects of this psychotomimetic drug [34].
On the other hand, the use of only the selective α2 adrenergic receptor antago-
nist does not impair the animal’s spatial memory, but dramatically aggravates the
phencyclidine-induced memory deficit [36]. These data demonstrate that α2
adrenergic receptors mediate the inhibition of spatial memory disturbances,
suggesting their important role in cognitive deficits associated to NMDA receptor
hypofunction [34, 36].
The role of moxonidine (an α2 adrenergic imidazoline I1 receptor agonist) on
cognitive function in rats with Huntington’s disease experimentally induced with 3-
nitropropionic acid (3-NPA) was investigated in the Morris swimming test and in
the elevated plus maze test. The administration of 3-NPA induces degenerative
brain damage, progressive motor dysfunction, loss of grip force, emotional distur-
bances, weight loss, anxiety, and impairment of learning activity and memory. An
increase in cerebral acetylcholinesterase level, enhancement of oxidative stress, and
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impairment of the activity of mitochondrial enzyme complexes I, II, and IV were
also noted [28]. The treatment with moxonidine resulted in the alleviation of dis-
turbances caused on animal weight, motor activity, gripping ability, anxiety,
impairment of learning ability and memory, and biochemical disturbances, thus
indicating that substances modifying the activity of I1 receptors may be potential
pharmacological agents for the treatment of degenerative brain disorders [55].
The effects of clonidine have also been evaluated in mice with subacute brain
ischemia obtained after permanent ligation of common carotid arteries. The subse-
quent brain damages consisted of expansion of cerebral infarction areas, assessed by
computed tomography scans. This experimentally induced chronic cerebral
hypoperfusion was associated with a significant impairment of animal’s learning
ability and memory in the Morris swimming test [25, 28]. Subacute treatment with
clonidine for 7 days increases the expression of neuronal nuclei, glutamic acid-
decarboxylase-67, and gamma-aminobutyric acid (GABA) B receptor (GABAB1) in
hippocampal subregion cornu amonis (CA1) but does not influence the level of
these elements in the hippocampal area CA3, nor in the dentate gyrus. These data
support the idea that clonidine exerts neuroprotective effects on chronic cerebral
ischemic lesions, by regulating GABAB1 receptors and the activity of glutamic acid-
decarboxylase-67 [25].
Additionally, the decrease in superoxide dismutase (SOD), catalase (CAT), and
glutathione levels as well as the increase of both malondialdehyde (MDA) level and
cerebral acetylcholinesterase activity were noted in animals with brain ischemic
lesions [28].
Both moxonidine and clonidine have shown a decrease in histopathological
changes, oxidative stress, central cholinesterase activity, as well as a reduction in
memory disturbances and learning deficits in mice with vascular dementia induced
by subacute ischemia after permanent bilateral cerebral artery ligation [28, 40].
In vitro cell culture studies from the rat frontal cortex with glutamate-induced
neurotoxicity revealed the partial neuroprotective effects of moxonidine, with a
significant decrease in the number of dead cells [26]. Moxonidine has shown bene-
ficial effects on cerebral spasm in an experimental rabbit model of subarachnoid
hemorrhage [40, 56].
5. The interrelations between the imidazoline system and the oxidative
stress in the mediation of cognitive functions
Different pathological conditions of the body, as well as the physiological pro-
cess of aging, can cause cognitive impairment and free oxygen radicals production,
being responsible for abnormal functioning and cell death. Subsequently, a new
idea has emerged claiming that nitric oxide (NO), along with the free radicals, plays
a key role in the aging process, due to neurotoxic effects on the brain exerted by its
excessive levels [57]. Nitric oxide is generated from L-arginine under the action of
nitric oxide synthase (NOS). The three isoforms of NOS have different roles in the
body: neuronal NOS (nNOS) is responsible for synaptic plasticity, learning and
memory processes; endothelial NOS (eNOS) provides stabilization and regulation
of vascular micro-environment and contributes to neuroplasticity [58]; and induc-
ible NOS (iNOS) is involved in various pathophysiological conditions [57].
Numerous experimental researches reveal that NOS activity is significantly ele-
vated in the brain of elderly rats, being associated with existing cognitive alterations
[57, 59]. Mediated by the competitive inhibition of nNOS and iNOS, and correlated
with the stimulation of NOS, agmatine contributes to the improvement of cognitive
functions [19, 60, 61], while exhibiting neuroprotective effects [38, 39].
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Literature data have shown that agmatine eliminates neuroinflammation and
lipopolysaccharide-induced memory impairment (which is known to stimulate
iNOS activity and, implicitly, the NO production) in laboratory animals. It prevents
cognitive alterations, probably as a result of inhibition of iNOS activity [39]. Other
researchers have disproved these results by showing that agmatine can cause cog-
nitive impairment due to the inhibition of NMDA receptors and of NO, important
elements in the modulation of learning and memory processes [62, 63].
On the other hand, it is known that the central cholinergic system plays a crucial
role in the mediation of cognitive functions. Cognitive deficits have been induced in
laboratory animals by using an anticholinergic agent, scopolamine, its administra-
tion producing a significant reduction in NOS activity, and an increase in arginase
activity, of L-ornithine and putrescine levels in the hippocampus [51]. It has been
observed that agmatine eliminates the scopolamine-induced alterations of memory
and learning capacity [64, 65].
Although glutamatergic activity is required for cognitive processes, it is assumed
that the increase of glutamate levels or of NMDA activity would also be responsible
for the scopolamine-induced cognitive disturbances [66].
Knowing that agmatine blocks NMDA receptors and also interferes with the
pathways of NO, NOS, and L-arginine, it was assumed that the removal of
scopolamine-induced cognitive deficits can be attributed to its modulating effect on
NO/NOS activity, on L-arginine, and also to the antagonization of NMDA recep-
tors, with subsequent suppression of excessive glutamatergic activity [61, 65].
Abnormal release and disturbances of neuromodulatory activities due to varia-
tion in cerebral agmatine levels may be correlated to different CNS diseases (such as
schizophrenia). Interactions of agmatine with other central neurotransmitter sys-
tems (such as glutamatergic and nitrergic) appear to be particularly important in
the pathophysiological mechanisms of CNS disorders associated with brain damage
and cognitive functions deficit.
6. The opioid system
Neurodegeneration can be caused by chronic disease progression or by acute
injury (cerebral ischemia—stroke or trauma) [67]. Ischemic stroke represents a
vascular ailment with neurological consequences produced by the obstruction of the
arteries in a part of the brain, therefore by blood supply privation [68]. Stroke can
determine long-term neurological and psychiatric impairments, its therapy being
focused on confining secondary injury processes [67].
In a recent review article, Chamorro presented that ischemic stroke is “the first
cause of permanent disability in adult people, the second single most frequent cause
of death for people older than 60 years, the second most common cause of demen-
tia, representing approximately 3% to 7% of the total health-care expenditure in
high income countries” [69].
A superpose of pathologies in different neurological disorders was proposed
since NDDs and ischemic stroke are frequently concomitant, hence the
neuroprotective therapy could be similar [70].
Opioids are substances with morphine-like action binding to specific opioid
receptors (ORs). In the early 1990s, three important opioid receptor families
[μ (MOR), κ (KOR), and δ (DOR)] were identified, and in 1994 another opioid
receptor was discovered [nociceptin, orphanin FQ receptor (NOP), or the opioid
receptor-like orphan receptor (ORL)]. ORs are found in the nervous system, lungs,
heart, liver, and gastrointestinal and reproductive tracts. They have been inten-
sively studied and it was emphasized that they not only are related to
9
Current Therapeutic Approaches from Imidazoline and Opioid Receptors Modulators…
DOI: http://dx.doi.org/10.5772/intechopen.81951
antinociceptive action, but also have a role in cell proliferation, ionic homeostasis,
emotional response, immune function, epileptic seizures, feeding, obesity, respira-
tory and cardiovascular control, hibernation, and neuroprotection [71, 72].
In the last decades, researches have pointed out that the opioid system can be
promising to get neuroprotective treatment in the event of stroke, through OR
agonists at lower doses, to avoid tolerance and/or physical dependency. DOR ago-
nists followed by KOR agonists have revealed the most intense neuroprotective
efficacy [64]. Major OR agonists tested for neuroprotection are listed in Table 2
[71, 72].
DOR activation is beneficial against ischemic, hypoxic, and excitotoxic injuries
[73]; recent studies promote DOR and especially DADLE (an analog of endogenous
delta-opioid enkephalin) as promising targets for treating NDDs like stroke and PD
[74–76].
DADLE alleviates apoptotic pathways, supports not only cell survival of periph-
eral organs (such as lung, heart, kidney, and liver) but also neuronal survival, and
protects neurons and glial cells from ischemia-induced cell death [76–78].
In a cellular model of PD, DADLE administration augmented cell survivability
with concurrent downregulation of the unfolded protein response stress sensors and
protein aggregates [79].
Findings from a rat middle cerebral artery occlusion (MCAO) stroke model
proposed that neuroprotection of DADLE treatment was based on the activation of
PI3K-Akt pathway by reducing nerve cell apoptosis [80].
Non-selective opioid receptor agonists were also tested: LYS739 (fluorinated
enkephalin-fentanyl derivative) and the most promising compound—biphalin—
which proved to be effective both in vitro and in vivo stroke models [72].
The latter is a dimeric enkephalin analog (Tyr-D-Ala-Gly-Phe-NH-)2 with high
potency and affinity for MOR and DOR and low affinity for KOR. Biphalin crosses
blood-brain barrier reaching spinal and supraspinal sites expressing OR and pro-
duces less physical dependence and tolerance compared to morphine [72, 81–84].
Opioid receptor Agonist
δ DADLE [D-Ala2, D-Leu5]-enkephalin
DPDPE (D-Pen2,D-Pen5)-enkephalin
SNC80
Tan-67
Remifentanil
κ BRL 52537
CI-977
GR89696
Salvinorin A
U-50,488H
Dynorphin
μ DAMGO [D-Ala2,N-MePhe4,Gly-ol]-enkephalin
Endorphin 1 and 2 (EM 1/2),
Morphine
Table 2.
Opioid receptors and their agonists tested for neuroprotective action.
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Different studies using a mouse MCAO stroke model reported that biphalin
reduced brain edema and infarction, ROS production, and NMDA-induced
excitotoxicity. It also increased locomotor activities and neurological score after
stroke resembled to saline-treated animals [72, 81, 85, 86]. Biphalin notably dimin-
ished penumbral expression of Na+, K+, 2Cl cotransporter (NKCC), and the trans-
location of the conventional isoforms of protein kinase C [81].
It has been hypothesized that biphalin’s neuroprotective effects are more intense
compared to subtype-selective agonists due to concomitant activation of the three
types of OR [72, 85].
7. Conclusion
Various pharmacological substances influencing the pathways of the main neu-
rotransmitters have confirmed valuable effects in neurogenesis and
neuroprotection, being validated in different in vitro researches and in vivo experi-
mental animal models of limited or extensive ischemic brain lesions.
Deciphering the roles of the neurotransmitters in central nervous system activity
other than the signaling function will represent a starting point to deepen the
knowledge about the complex mechanisms of the brain functions and to obtain new
agents useful for protection of ischemic neurons and for preventing their irrevers-
ible damage.
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